Xin Lang Cai Jing·2025-12-02 01:24Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating high levels of financing and short selling [1] - On December 1, Junshi Biosciences' stock fell by 1.59%, with a trading volume of 209 million yuan, and a net financing outflow of 207.43 million yuan [1] - The total financing and securities balance for Junshi Biosciences reached 1.378 billion yuan, with the financing balance accounting for 4.89% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an increase of 35.72% year-on-year [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]